Stock Ticker

  • Loading stock data...

Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen SA (EPA:IPN) have a new phase of development for their Cabometyx™ (cabozantinib). The treatment that comes in 20, 40, and 60mg a which is use in the treatment of advanced renal cell carcinoma (RCC) in adults has received positive recommendation from Committee for Medicinal Products for Human Use (CHMP). The recommendation […]

Exelixis, Inc. (NASDAQ:EXEL) To Cut 160 Jobs After failure of Prostate Cancer Trial

Boston, MA 09/03/2014 (wallstreetpr) – According to recent reports, Exelixis, Inc. (NASDAQ:EXEL) has decided to slash around 160 jobs due to failure of protest cancer trial. The stock prices of EXEL hit all time low after it announced that its drug Cometriq failed at a later stage. The company was trying to find a solution […]

Piper Puts Stop To Exelixis, Inc. (NASDAQ:EXEL)’s Free-Fall

Boston, MA 04/07/2014 (wallstreetpr) – Exelixis, Inc. (NASDAQ:EXEL)‘s free-fall driven by its idea of continuing late-stage trial of its prostate cancer drug appears to have come to a halt since the time analyst at Piper Jaffray encouraged buyers in the stock. Apart from this, the company recently received European commission’s approval for its Thyroid cancer drug. […]

Stocks On The Watchlist: Exelixis, Inc. (NASDAQ:EXEL); Sungy Mobile Ltd (NASDAQ:GOMO) And Ballard Power Systems Inc. (USA) (NASDAQ:BLDP)

Boston, MA 03/27/2014 (wallstreetpr) – Exelixis, Inc. (NASDAQ:EXEL) is recovering today after its plunge yesterday by close to 40% post the company’s statement that it wants to take its clinical trial forward. The study trial relates to testing its drug cabozantinib aimed at treating patients with prostate cancer. Although the continuation of the trial does […]

Exelixis, Inc. (NASDAQ:EXEL): Not Coming Soon

Boston, MA 03/26/2014 (wallstreetpr) – Exelixis, Inc. (NASDAQ:EXEL)’s prostate cancer drug candidate which showed positive results in the Phase II of clinical trial will not come to the market soon. The company announced Tuesday that an independent monitoring committee has recommended that it continues with the Phase III study of the drug. The company is seeking […]

Sign Up To Get Our Latest Stocks Alerts